As confirmed above, CCBL2 had significantly strong relation with ER (p = 0.0005) and PR (p = 0.0005) status, accounting for the lower expression of CCBL2 in tumor cells of basal-like/Her-2-enriched BC and higher expression in luminal A (ER/PR-positive) BC cells. Here, ERBB2 is linked to breast cancer.